

Accreditation and Designation Statements and Disclosure Report

LUGPA 2026 Global Prostate Cancer Congress

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUGPA. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live and enduring formats for this educational activity for a maximum of *9.25 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activities.

The live approval period is: January 10-13, 2026

The enduring approval period is: February 10, 2026 – February 10, 2029

Financial Disclosures.

The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:

“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”

Full Legal Name	Commercial Interest	Role	Level of participation in the activity
David Albala	Applied Medical	Stock/Stock Options	Speaker
	MDx Health	Researcher/Investigator	
Marijo Bilusic	Bicycle Therapeutics, Pfizer, Clasp Therapeutics, Hookipa Pharma, Eli Lilly, Marengo Therapeutics, Surface Oncology, Merck Sharp & Dohme,	Research Funding	Speaker
	Tolmar	Consultant	Speaker
Renee Cherry	Exosome, Astellas Amgen, Janssen, Veracyte, GSK, Pfizer, LynxDx	Consultant	Speaker
E. David Crawford	Janssen, Bayer, MDx, Tolmar	Consultant	Speaker/Planner/Reviewer
	Pfizer, Astellas	Speaker	
	Carden Jennings	Advisor	
Jason Efstathiou	Boston Scientific, Bioprotect, Astellas/Pfizer, MDxHealth,	Consultant	Speaker

	Clarity Pharmaceuticals		
	Janssen/Johnson & Johnson	Advisor	
Scott Eggener	A3P biomedical, Janssen	Consultant	Speaker
	Candel Therapeutics	Researcher/Investigator	
Jason Hafron	Novartis, Urogen, Bayer, Myriad, Dendreon, Janssen Biotech, Astellas, Immunis AI Scientific, AZ, Merck, Photcure, Lilly, ArteraAI, Sumitomo	Consultant	Speaker
	Lipella, mIR Scientific Progenics	Researcher/Investigator Speaker	
Ron Kaufman	Clarity, Ferring. SUO-CTC-ECOG-ACRIN, Stebabiotech, Becton, Dickison & Company, Pacific Edge Diagnostics, enGene, Janssen	Research Funding	Speaker
Michael Liss	Oncobiomix	Ownership Interest	Speaker
Benjamin Lowentritt	Pfizer, Sumitomo Pharma, Astellas, Merck, AstraZeneca, Bayer	Advisor	Speaker
	Johnson & Johnson, Cencora Specialty Networks	Consultant Ownership Interest	
	Dendreon, Novartis	Researcher/Investigator	
Travis Mendel	GE, Novartis	Advisor	Speaker
	BostonSci, Novarts BioProtect	Researcher/Investigator Consultant	
Todd Morgan	Pfizer, Johnson & Johnson, Merck, Foundation Medicine	Consultant	Speaker
David Morris	Pfizer, Merck, AZ, Bayer, Dendreon, Decipher, Telix, Johnson & Johnson, Caris, Sumitomo, Veritas, Astellas	Consultant	Speaker. Planner/Reviewer
Diane Newman	NIH, Hollister	Researcher/Investigator	Speaker
	Sumitomo, COSM, Innocare, Convatec, Urology Health	Advisor	
	Grand Rounds in Urology	Editor	
Scott Sellinger	Avyxa, Astellas, Sumitomo, Bayer, Foundation Medicine, Tempus, MDX Health, Accord Biopharma, AZ, Johnson & Johnson, Pfizer	Consultant	Speaker, Planner/Reviewer

These financial relationship(s) with ineligible companies have been mitigated by PeerPoint Medical Education Institute and the LUPGA.

All other presenters, planners, editors, or staff report no relationships to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."